Mucin O-Glycosylation and Mucolytic Therapies in Pseudomyxoma Peritonei: Literature Review

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Pseudomyxoma peritonei (PMP) is characterized by mucus accumulation.
• Mucins, particularly mucin2 (MUC2), are key components of PMP mucus, contributing to its viscoelasticity.
• Effective mucolytic therapy is crucial for improving treatment efficacy and patient prognosis in PMP.

Purpose of the Study:

• To review the molecular pathological mechanisms of PMP.
• To detail the processes of mucin O-glycosylation and mucolytic therapies in PMP.
• To identify potential therapeutic targets for PMP treatment focused on mucin O-glycosylation.

Main Methods:

• Literature review on PMP pathology, mucus composition, and mucin structure/function.
• Detailed investigation of MUC2 O-glycosylation synthesis in the endoplasmic reticulum and Golgi apparatus.
• Summary of current and potential mucolytic and mucin secretion inhibitory therapeutic approaches.

Main Results:

• Mucins are highly O-glycosylated proteins central to PMP mucus.
• MUC2 O-glycosylation synthesis involves complex enzymatic and substrate pathways.
• Several therapeutic strategies targeting O-glycosylation pathways show promise for PMP treatment.

Conclusions:

• Understanding mucin O-glycosylation is vital for developing effective mucolytic therapies for PMP.
• Targeting O-glycosylation substrates and enzymes offers potential therapeutic avenues.
• This review provides a reference for future PMP mucolytic therapy development.